Recommendations for management of carriers or BRCA1 and BRCA2 gene mutations (adapted from Burke et al12 )
| Topic | Recommendation (expert opinion) |
| Breast self examination | Education regarding monthly examination |
| Clinical breast examination | Annually beginning at age 25–35 |
| Mammography | Annually beginning at age 25–35 |
| Transvaginal ultrasound (with colour Doppler) | Annually beginning at age 25–35 |
| Bilateral mastectomy | Insufficient evidence to recommend for or against1-150 |
| Bilateral oophorectomy | Insufficient evidence to recommend for or against |
| Oestrogen replacement | Insufficient evidence to recommend for or against1-150 |
| Chemoprevention (for example, tamoxifen) | Insufficient evidence to recommend for or against1-150 |
↵1-150 There is evidence that these interventions may reduce the risk of cancer in individuals at high risk of breast or ovarian cancer, but data specific to patients with BRCA mutations are lacking.